Select Page

Investor Relations

Stocktwits

News

    Events

    Webcasts & Presentations

      Reports & Filings

          Date Filing Description Download

            Stock Information

            Stock Quote: NASD

            Price 0.27
            Change +0.00
            Volume 3,037,100
            % Change +0%
            Intraday High 0.31
            52 Week High 0.95
            Intraday Low 0.27
            52 Week Low 0.13
            Today's Open 0.31
            Previous Close 0.27
            May 03, 2016 05:00 PM Pricing delayed 20 minutes
            Analyst Firm
            Jason Kolbert Maxim Group, LLC
            Joseph Pantginis, Ph.D. Roth Capital Partners
            Henry W. McCusker Scimitar Equity
            Stephen G. Brozak WBB Securities, LLC

            Cytori Therapeutics is followed by the analyst(s) listed above. Please note that any opinions, estimates or forecasts regarding Cytori Therapeutics's performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of Cytori Therapeutics or its management. Cytori Therapeutics does not by its reference above or distribution imply its endorsement of or concurrence with such information, conclusions or recommendations.

            Computershare Investor Services

            Mailing Addresses
            Shareholder correspondence should be mailed to:
            Computershare
            P.O. BOX 30170
            College Station, TX 77842-3170

            Overnight correspondence should be sent to:
            Computershare
            211 Quality Circle, Suite 210
            College Station, TX 77845

            Shareholder Website
            www.computershare.com/investor

            Shareholder Online Inquiries
            www-us.computershare.com/investor/Contact

            Management Team

            Marc H. Hedrick, M.D. , , , President/CEO

            Dr. Marc H. Hedrick was appointed President in May 2004 and CEO in 2014. Dr. Hedrick joined Cytori Therapeutics as Chief Scientific Officer, Medical Director and Director in October 2002. Previously, Dr. Hedrick co-founded, and served as President and Chief Executive Officer of StemSource, Inc., a company specializing in stem cell research and development. Dr. Hedrick, a plastic surgeon by training, is a former Associate Professor of Surgery and Pediatrics at the University of California, Los Angeles (UCLA). From 1998 until 2005, Dr. Hedrick directed the Laboratory of Regenerative Bioengineering and Repair for the Department of Surgery at UCLA. Dr. Hedrick obtained his M.D. from the University of Texas Southwestern Medical School, Dallas and an M.B.A from UCLA in 2005.

            Tiago M. Girão , , , Vice President of Finance and Chief Financial Officer

            Mr. Tiago Girão was appointed Vice President of Finance and Chief Financial Officer (CFO) in September 2014. Mr. Girão joins Cytori Therapeutics from NuVasive, Inc. where he recently served as International Controller. Prior to his International Controller role, he served as Director, Financial Reporting, where he managed a team responsible for all corporate technical accounting and SEC related matters. Prior to joining NuVasive, Mr. Girão served as Senior Manager, Assurance at KPMG, Cytori’s independent audit firm and was responsible for Cytori’s account for six years. Prior to joining KPMG, Mr. Girão was a senior accountant for Ernst & Young in Brazil. Mr. Girão is a certified public accountant with 14 years experience in the accounting, finance and reporting for U.S. public companies and substantial experience in global finance and operations.

            Steven Kesten, M.D. , , , Executive Vice President & Chief Medical Officer

            Steven Kesten joined Cytori as Executive Vice President and Chief Medical Officer in February 2013. Previously, he served as Vice President and Chief Medical Officer at Uptake Medical and at Boehringer Ingelheim, mostly recently as the vice president, medicine for marketed products for respiratory disease. Prior to that, he served as the medical director of the Rush Advanced Lung Disease and Lung Transplant Program at Rush Presbyterian St. Luke’s Medical Center; as the medical director of the Toronto Lung Transplant Program at the University of Toronto; and as a staff pulmonologist at Toronto General Hospital and Toronto Western Hospital. He also served as a faculty member of the University of Toronto and an associate professor of medicine at Rush Medical College. Dr. Kesten received his medical degree and specialty training in internal medicine and pulmonary medicine at the University of Toronto.

            Kenneth K. Kleinhenz , , , Vice President, Global Regulatory Affairs

            Kenneth K. Kleinhenz was appointed Vice President, Global Regulatory Affairs in April 2013. Previously, he had served as our Vice President of Regulatory Affairs & Quality Assurance since November 2007 and as Director of Regulatory Affairs since joining us in 1999. From September 1998 to June 1999, Mr. Kleinhenz was the Technical Director of IFM Manufacturing. He served as a Chief Microbiologist for Becton Dickenson from June 1997 to September 1998, and as Manager of Quality Assurance and Regulatory Affairs at Pacific Pharmaceuticals from September 1993 to June 1997. Mr. Kleinhenz is a veteran of the United States Navy, where he served as a Clinical Microbiologist for six years at the Naval Hospital, San Diego. He earned his B.S. in Microbiology at the University of California, San Diego (UCSD) and his M.B.A. in Technology Management at the University of Phoenix.

            John K. Fraser, PhD , , , Chief Scientist

            Dr. John Fraser is the Chief Scientist at Cytori Therapeutics Inc. Prior to joining Cytori, Dr. Fraser had a 12 year career in the Department of Medicine at UCLA. Before joining Cytori, he was the Director and Principal Investigator of the UCLA Umbilical Cord Blood Bank, a NIH-funded allogeneic cord blood stem cell bank. Dr Fraser has a PhD from the University of Otago in New Zealand and a Bachelor of Science degree (Biochemistry and Physiology) from Victoria University of Wellington. He has published more than 40 peer-reviewed papers, has 12 patents issued in the USA. During his career has been awarded more than $12 million in research contract and grant funding from the National Institutes of Health.

            Lisa Hellmann Rhodes , , , VP HR & Communications

            Lisa Hellmann Rhodes joined Cytori in 2015 as Vice President, Human Resources and Communications, responsible for leading strategic human resources and communications. In this role, she business partners with leaders across the company to ensure that Cytori’s strategy is clearly developed, articulated and effectively executed, both externally and internally, and drives the identification and building critical the talent and cultural elements necessary to fuel future growth and successful achievement of the strategic vision. Prior to joining Cytori, Lisa served as Chief People Officer at Millennium Health, where she worked with leaders across the business to lead the transformation from rapidly growing start-up to a robust, scalable enterprise, while nurturing the critical elements of the legacy culture. She supported the development of the Human Resources team to anticipate the needs of the rapidly growing, highly diverse workforce, strengthen leadership capability across the organization, while building the necessary infrastructure processes to simplify and scale critical business functions to support increasing complexity and scale of enterprise. Lisa’s background includes more than 20 years of experience contributing to global, fast-paced, growing biotechnology and high technology organizations, holding various leadership positions at Hologic, Gen- Probe, Biogen Idec, Memec and Accenture. Lisa has her bachelor’s degree in human biology from Stanford University and her master’s degree in human resources leadership from Rutgers University.

            Jeremy Hayden , , , General Counsel & VP Business Development

            Mr. Jeremy Hayden serves as our General Counsel and Vice President of Business Development, positions he has held since July 2015. Mr. Hayden joined Cytori from Volcano Corporation, where he served as Assistant General Counsel. Prior to his tenure at Volcano, Mr. Hayden practiced corporate and securities law at several international law firms, including McKenna Long & Aldridge, LLP and Mintz Levin Cohn Ferris Glovsky & Popeo, P.C. Mr. Hayden received his A.B. in Politics from Princeton University and his J.D. from the University of Michigan Law School.

            John Harris , , , Vice President & General Manager of Cell Therapy

            Joining Cytori Therapeutics in October of 2015, John D. Harris serves as the Vice President & General Manager of Cell Therapy. Mr. Harris has 20+ years experience in medical device and biotechnology, most recently serving as the Vice President and General Manager of Becton Dickinson’s operations in Japan. Prior to BD, Mr. Harris held Business Development, Product Development, Marketing and Sales leadership roles with Tyco Electronics, Delphi, Sorenson Medical, Kimberly-Clark Healthcare and Ballard Medical Products. Mr. Harris is a member of the Board of Governors of the American Chamber of Commerce in Japan (ACCJ) and a member of the Executive Committee of the American Medical Device & Diagnostics Association (AMDD), where he chairs the Regenerative Medicine Working Group. Mr. Harris holds Master of Business Administration (MBA) and Bachelor of Arts (BA) degrees from University of Utah.

            Cheri Rice , , , Vice President, Portfolio Management and Development

            Cheri Rice was appointed Vice President, Portfolio Management and Development at Cytori Therapeutics, Inc. in August of 2015. Prior to joining Cytori, she served as Vice President of Disposable Development for Volcano Corporation, a leading developer of intravascular ultrasound diagnostic equipment from June 2008 until May 2015. Prior to Volcano she worked her way up through the ranks at Abbott Vascular, ending her tenure as Manager of Process Development. She brings 27 years of Program Management and Engineering in experience to Cytori. Cheri has her bachelor’s degree in Mechanical Engineering from San Diego State University.

            Board of Directors

            David M. Rickey , , , Chairman

            David M. Rickey has served as a Director of the Company since November 1999 and was appointed Chairman in June 2013. Mr. Rickey was President and Chief Executive Officer of Applied Micro Circuits Corporation (AMCC) from February 1996 to March 2005. Mr. Rickey served on the Board of Directors of AMCC from February 1996 to March 2005, and as its Chairman of the Board from August 2000 to March 2005. Mr. Rickey also served as a Director of AMI Semiconductor, Inc. from 2000 to 2006 and was a Director of Netlist, Inc. from 2005 to 2008, as well as several private technology companies. He holds a B.S. from Marietta College, a B.S. from Columbia University and an M.S. from Stanford University.

            Richard J. Hawkins , , , Director

            Richard J. Hawkins joined us as Director in December 2007. Mr. Hawkins is currently the CEO of Lumos Pharma, Inc., a start-up pharma company. Mr. Hawkins founded LabNow Inc., a diagnostic device company developing rapid, point-of-care, physician office-based diagnostic testing systems, and served Chairman and CEO from 2004 until October 2009. Mr. Hawkins previously founded and guided the growth of Pharmaco, a clinical drug development services company where he served as Chairman, President, and Chief Executive Officer. He is a founder of id2, a pharmaceutical and biotechnology research management company, Sensus Drug Development Corp., a biotechnology company that was sold to Pfizer, and Covance Biotechnology Services, and served as Chairman of the Board for LoopOne, Inc., a shipping and logistics software company. Mr. Hawkins holds a B.S. in biology from Ohio University.

            Paul W. Hawran , , , Director

            Paul W. Hawran joined Cytori Therapeutics as Director in February 2005. Mr. Hawran is the founder of and currently serves as President and CEO of Ascendant MDx, a molecular diagnostic testing company. Previously, he served as Chief Financial Officer of Sequenom, Inc., from April 2007 to September 2000 and served on their Board of Directors from August 2006 to February 2007. He previously served as Executive Vice President and Chief Financial Officer of Neurocrine Biosciences, Inc. from May 1993 through September 2006. Mr. Hawran has also held executive management positions at SmithKline Beecham (now Glaxo SmithKline), most recently as Vice President and Treasurer. Prior to joining SmithKline (Beecham) in 1984, he held various financial positions at Warner Communications (now Time Warner) involving corporate finance, financial planning and domestic and international budgeting and forecasting. Mr. Hawran received a B.S. in finance from St. John's University and an M.S. in taxation from Seton Hall University. He is a certified public accountant and a member of the American Institute of Certified Public Accountants.

            Gary A. Lyons , , , Director

            Gary A. Lyons joined Cytori as a Director in October 2013. Mr. Lyons has served on the Board of Directors of Neurocrine Biosciences since 1993 and as the President and Chief Executive Officer of Neurocrine from 1993 through January 2008. Prior to joining Neurocrine Biosciences, Mr. Lyons held a number of senior management positions at Genentech, Inc., including Vice President of Business Development and Vice President of Sales. Mr. Lyons currently serves on the Boards of Directors for Rigel Pharmaceuticals, Inc., Vical Incorporated, and KaloBios Pharmaceuticals, Inc. Mr. Lyons was previously a director of PDL BioPharma, Inc., Poniard Pharmaceuticals, Inc., Neurogesx and Facet Biotech Corporation. Mr. Lyons holds a B.S. in marine biology from the University of New Hampshire and an M.B.A. from Northwestern University’s J.L. Kellogg Graduate School of Management.

            Gail K. Naughton , , PhD , , Director

            Gail K. Naughton, PhD joined Cytori Therapeutics’ Board of Directors as a director in July 2014. Dr. Naughton was the co-founder and co-inventor of the technology at Advanced Tissue Sciences where she held key management positions for more than 15 years, including President, Chief Operating Officer and Director. She also served as the Dean of the College of Business Administration at San Diego State University for nine years. Currently, Dr. Naughton serves as the Chief Executive Officer and the Chairman of the Board of Histogen, a regenerative medicine company she founded in 2007. Dr. Naughton also currently serves on the Board of Directors for CR Bard, Inc. Dr. Naughton holds a B.S. in Biology from St. Francis College as well as a Master’s in Histology and a PhD in cell biology from New York University Medical Center. She also holds an EMBA from the Anderson School at the University of California, Los Angeles.

            Tommy G. Thompson , , , Director

            Tommy G. Thompson joined us as a Director in April 2011. Mr. Thompson was a partner at the law firm of Akin Gump Strauss Hauer & Feld from March 2005 to January 2012. He served as U.S Department of Health and Human Services Secretary from January 2001 to January 2005, and was Governor of Wisconsin from November 1986 to January 2001. Mr. Thompson was the Chairman of the Board of Logistics Health, Inc., having been President from February 2005 to January 2011. Mr. Thompson has served as a Director of C.R. Bard since August 2005; a Director of CareView Communications, Inc. since July 2005; a Director of Centene Corporation since April 2005 and a Director of United Therapeutics Corporation since February 2011. He also served as Chairman of the Board of AGA Medical Corporation from July 2005 to November 2011. He is a recipient of the prestigious Horatio Alger Award and has served as chairman of the National Governors’ Association, the Education Commission of the States, and the Midwestern Governors’ Conference. Mr. Thompson received both his B.S. and his J.D. from the University of Wisconsin-Madison and also served in the Wisconsin National Guard and the Army Reserve.

            Marc H. Hedrick , , , President/CEO

            Dr. Marc H. Hedrick was appointed President in May 2004 and as CEO in 2014. Dr. Hedrick joined Cytori Therapeutics as Chief Scientific Officer, Medical Director and Director in October 2002. Previously, Dr. Hedrick co-founded, and served as President and Chief Executive Officer of StemSource, Inc., a company specializing in stem cell research and development. Dr. Hedrick, a plastic surgeon by training, is a former Associate Professor of Surgery and Pediatrics at the University of California, Los Angeles (UCLA). From 1998 until 2005, Dr. Hedrick directed the Laboratory of Regenerative Bioengineering and Repair for the Department of Surgery at UCLA. Dr. Hedrick obtained his M.D. from the University of Texas Southwestern Medical School, Dallas and an M.B.A from UCLA in 2005.

            Board Committees

            Charters

            Download
            Audit Commitee Charter 562 KB
            Compensation Committee Charter 173 KB
            Governance & Nominating Charter 167 KB
             = Chair    = Member
            Committee Member
            Richard J. Hawkins
            Audit
            Governance & Nominating
            Paul W. Hawran
            Audit
            Tommy G. Thompson
            Audit
            Compensation
            Gary A. Lyons
            Compensation
            Governance & Nominating
            Gail Naughton
            Compensation
            Governance & Nominating
            Committee Member Audit Compensation Governance & Nominating
            Richard J. Hawkins


            Paul W. Hawran


            Tommy G. Thompson


            Gary A. Lyons


            Gail Naughton


             = Chair    = Member

            Corporate Governance  Materials

            Download
            Cytori Therapeutics Comprehesive Compliance Program
            Code of Business Conduct & Ethics 701 KB
            Ethics Point

            Meetings & Proxy Materials

            Annual Stockholder Meeting
            Date: May 10, 2016
            Time: 9 AM PST
            Location: Cytori Therapeutics, Inc.
            3020 Callan Rd. San Diego, CA 92121

            Record Date: March 11, 2016

            Electronic Proxy & Stockholder Material
            Cytori Therapeutics is pleased to offer stockholders the option of electronic delivery of its proxy statements and annual 10-K for the 2016 annual meeting. Electronic delivery benefits Cytori and its stockholders through the reduction of printing costs and paper usage, thereby benefiting the environment. We encourage you to enroll.

            Download
            2015 Annual Report & Proxy Statement 4.00 MB
            CEO’s Letter to Stockholders 100 KB

            Information Request

            Email Address:*  
            First Name:*  
            Last Name:*  
            Company:
            Address1:
            Address2:
            Postal Code:
            Country:
             
            Enter the code shown above.
             

            Investor Relations Contact

            Cytori Therapeutics, Inc.
            Tiago Girao
            Chief Financial Officer
            Phone: 2041-858-458-0900
            Email: ir@cytori.com

            PCG Advisory
            Vivian Cervantes
            Investor Relations
            Phone: (212) 554-5482
            Email: vivian@pcgadvisory.com

            RSS Feeds

            What is RSS?

            Really Simple Syndication (RSS) is a technology that allows you to receive updated news from preferred websites, which are sent directly to the user's news reader. This includes the headlines, summaries and links to the full article on the website.

            What are the benefits of using RSS?

            RSS is an easy way to be notified about updated content on a website. Instead of having to visit a particular website, RSS will automatically send a notification when the subscribed section has been updated.

            How can I sign up to RSS feeds?

            To subscribe to an RSS feed, select the location of the website of interest and click the small orange button (these buttons usually only exist on the Events, Press Releases, and Presentations) to subscribe to the RSS feed. Next, simply follow the instructions for the particular RSS reader being used.

            Email Alerts

            Email Address *
            Mailing Lists *





             
            Enter the code shown above.

            Unsubscribe

            Email Address:  *